Latest News and Press Releases

Emerging mutations to the coronavirus are unlikely to affect Brilacidin’s ability to inhibit the virusBrilacidin currently is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19...

Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United...

New in vitro data also demonstrates Brilacidin’s anti-SARS-CoV-2 potency is unlikely to be impacted by mutations in different strains of the virus WAKEFIELD, Mass., Nov. 16, 2020 (GLOBE...

Preprint article details research conducted at George Mason’s Regional Biocontainment Laboratory: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing...

Brilacidin and Remdesivir shown to act synergistically in vitro, increasing overall inhibition against the novel coronavirus to 99.85 percent in a human lung cell lineData suggest that Brilacidin and...

Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be greater than 300 in a human lung epithelial cell lineBrilacidin’s...

Brilacidin is showing consistent and robust antiviral activity across the viral lifecycle in human lung and Vero cells; potential as a treatment for preventing infection with COVID-19, as well as for...

WAKEFIELD, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing...

WAKEFIELD, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned...

Data From Ongoing Testing at U.S. Regional Biocontainment Laboratory Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties...